Diabetes (Type 2 ), taking METFORMIN

    Not Recruiting
  • sponsor
Updated on 23 November 2020


Diabetes (Type 2 ), taking METFORMIN


Merck is conducting a clinical research study for adults who are at least 25 years of age and have been diagnosed with type 2 diabetes. The purpose of this study is to compare the safety and effectiveness of the oral medications sitagliptin versus dapagliflozin for the treatment of type 2 diabetes as an add-on to metformin. The use of these medications combined with metformin is investigational.

Approximately 550 volunteers around the world will participate in this clinical research study.

The study medication will be provided to study participants at no charge. Nutrition and exercise counseling will also be provided.

The purpose of the study is to assess the effect of the addition of sitagliptin to metformin compared with the addition of dapagliflozin to metformin on hemoglobin A1c (A1C) over 24 weeks of treatment


ClinicalTrials.gov identifier: NCT02532855

ClinicalTrials.gov identifier: NCT02532855

Condition Diabetic Kidney Disease, NIDDM, Kidney Disease
Clinical Study IdentifierTX144229
Last Modified on23 November 2020

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note